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Abstract

Keywords: Psychotropic medication, Polypharmacy,
Residential care, Children and adolescents, Latent
Class Analysis

High levels of psychotropic medication use and polypharmacy are common for emotionally and behaviorally troubled youth entering residential care. Polypharmacy has
often been characterized as an especially serious problem in this vulnerable population. Latent Class Analysis was used to identify medication subgroups for 636
youth in an intensive residential program. Additionally, auxiliary analyses (e.g., diagnoses, demographics,
expressed problem behaviors) were used to identify the
personal and behavioral attributes associated with individuals in each of the latent classes. Three distinct medication patterns emerged: low/no psychotropic medication, the combination of antidepressant and antipsychotic
medications, and multiple psychotropic medications. The
latent classes were signiﬁcantly different from one another on 12 of the 14 variables, helping explicate how
patient and clinical characteristics underlie patterns of
psychotropic medication use. Findings of this study, combined with additional research, hold promise for leading
to improved, youth-centered prescribing practices. Our
ﬁndings also highlight the need for careful monitoring
of the types and range of medications that some youth
are prescribed, and research on how youth with certain
background characteristics are more likely to get prescribed multiple psychotropic medications. For youth experiencing higher levels of psychotropic polypharmacy,
medication regimens need thoughtful reassessment using the principle of sufﬁciency as the foundation for medication management.

Introduction
For youth in need of emotional and behavioral intervention, oftentimes there are high levels of psychotropic medication use (Comer et al. 2010). For example,
the use of off-label (i.e., prescribing a drug for a condition other than that for which it has been ofﬁcially approved) atypical antipsychotic medications has increased
over the last 10 years (Harrison et al. 2012; Olfson et al.
2010; Rubin et al. 2012). A review of relevant literature
found that polypharmacy (i.e., treatment using two or
more psychotropic medications) increased 5.1 fold, from
4.8% to 24.7% for youth on a stimulant between 1996
and 2002 (Safer et al. 2003). An examination of Medicaid claims found a 6.2 fold increase in polypharmacy from
6.7% to 41.6% for depressed adolescents between 1996
and 2005 (McIntyre and Jerrell 2009). Similarly, between
1996 and 2007, the polypharmacy rate increased from
14% to 20% for youth prescribed psychotropic medication by an ofﬁce-based physician (Comer et al. 2010), and
has been reported to be as high as 60% for youth seeing
an ofﬁce-based psychiatrist (Mojtabai and Olfson 2010).
An additional challenge in this area is that youth experiencing polypharmacy tend to be on medications from
multiple psychotropic medication categories (e.g., mood
317
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stabilizers and antipsychotics) and even prescribed multiple medications within any given category (Comer et al.
2010; Spellman et al. 2010). The growing trend for youth
to be on two or more medications far outpaces our capacity to evaluate and assess efﬁcacy and safety (Saldaña
et al. 2014; Tishler and Reiss 2012; Vitiello 2007). There
is particular concern in relation to the adverse effects
of psychotropic medications to the developing brain and
body of children and adolescents (Correll and Carlson
2006; Singh and Chang 2012).
Youth in out-of-home care settings are at much
higher risk for polypharmacy, and it is especially prevalent in residential care settings where it is more the
rule than the exception (Brüggemann et al. 2008). Indeed, research examining youth in intensive, restrictive
residential programs has found that between 78% and
88% of youth were on a psychotropic medication at admission, with 57–67% being on two or more psychotropic medications (Huefner et al. 2014; Lyons et al. 2004).
Although elevated rates of polypharmacy use might be
due to higher mental health needs, this practice nonetheless poses a much higher chance of potential health
risks (Huefner et al. 2014; GAO 2011). Most psychotropic medication research has focused on monopharmacy
(i.e., treatment using a single medication), whereas relatively little has examined polypharmacy (Taylor 2010;
Vitiello 2005). While some polypharmacy combinations
are supported by effectiveness trials, most are of unproven efﬁcacy and may put patients at increased risk
of drug interactions with uncertain gains in terms of
quality of care or improved clinical outcomes (Mojtabai
and Olfson 2010). For example, although it has been observed that the use of combined medications for youth
with comorbid disorders or complex symptom presentation may be clinically justiﬁed and effective in certain
instances (Gadow et al. 2016; Linton et al. 2013; Pappadopulos et al. 2003; Wilens 2009), these studies are almost exclusively based on case reports and small-scale,
non-blind assessments (Safer et al. 2003).
More often than not, however, the psychotropic polypharmacy pattern for youth does not match a researchsupported combination. For example, Pruitt and Kiser
(2004) found the most frequently occurring multi-psychotropic combinations for children with serious emotional disturbance receiving treatment at a university
school of medicine clinic were 1) mood stabilizer with
an antidepressant or antipsychotic (9.4%), 2) antidepressant with a stimulant (9.4%), 3) stimulant with an
alpha agonist (7%), and 4) mood stabilizer, antidepressant, antipsychotic, and alpha agonist (5%). The complexity of polypharmacy patterns following current practice for troubled youth presents a tremendous challenge
to practitioners and researchers. Beyond the work of
Pruitt and Kiser (2004), we do not yet know the common patterns, especially for those youth most likely to

be on psychotropic medications (e.g., highly troubled
emotionally and behaviorally disordered youth like those
found in residential care settings). Additionally, because
of exclusionary criteria utilized in randomized clinical
trials, there is limited empirical data on the treatment
of youths with complex and comorbid conditions (Martin et al. 2003).
Most psychotropic medication research has examined individual medications, or even psychotropic medication subtypes (e.g., stimulants, antipsychotics, antidepressants) in isolation, whereas research has shown that
in practice they frequently are used in a complex array of
combinations. To tap into these complex combinations,
Latent Class Analysis (LCA) can be utilized. LCA is a person-centered analytic technique designed to identify subgroups of individuals with distinctive proﬁles/patterns
(Jobe-Shields et al. 2015; Lanza et al. 2003). A key feature of LCA is that subgroup membership is not known
and must be inferred from the data (Berlin et al. 2014).
LCA has been used to identify underlying patterns of illegal drug and alcohol use, as well as levels of disturbance
within individuals with posttraumatic stress disorder
(e.g., Green et al. 2010; Hedden et al. 2010; Patra et al.
2009; Ramo et al. 2010). LCA has not, insofar as we can
determine, been used to examine patterns of psychotropic polypharmacy. The promise of this research is to produce ﬁndings with practical and empirical signiﬁcance
for understanding and classifying psychotropic medication use in children and adolescents.
Prior research examining psychotropic polypharmacy
has used a wide range of variables in order to better understand and explain what increases the likelihood of
polypharmacy in child and adolescent populations. For
instance, research has shown that psychotropic polypharmacy has been related to sex, race, age, maltreatment,
and out-of-home placement history. Speciﬁcally, polypharmacy has been shown to be related to being male
(Dean et al. 2006) and Caucasian (Raghavan and McMillen 2008), however the literature is inconsistent (e.g.,
Grifﬁth et al. 2010; Logan et al. 2015). Polypharmacy is
also related to being older at the time of admission (Dean
et al. 2006), being younger at ﬁrst out-of-home admission (Fite et al. 2008; Li et al. 2015), to having a history of
maltreatment (Fontanella et al. 2009; Schilling and Christian 2014), and having experienced a greater number of
out-of-home placements (Saldaña et al. 2014; Stambaugh
et al. 2012). Additionally, researchers have also found that
polypharmacy is related to clinical factors, such as diagnosis and current behavior problems (Logan et al. 2015;
Raghavan and McMillen 2008). However, no research to
date has examined these variables in relation to distinct
patterns of polypharmacy reﬂecting speciﬁc combinations
of medication use found among youth in a residential care
setting. To address this gap, these variables will be used
as predictors of medication classes identiﬁed via LCA.
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This study represents an initial and unique attempt
at identifying and describing naturally occurring groups
of psychotropic medication usage among youth entering
residential care, and if youth characteristics such as age,
out-of-home placement history, diagnosis, and level of
disruptive behavior are related to those patterns.

Method
Participants
The sample for this study included all youth who were
admitted for the ﬁrst time to an intensive residential program in the Midwest (US) between January 2008 and October 2014 (n = 636). The treatment model for this psychiatric residential treatment facility (PRTF) is based on
a modiﬁed teaching-family model (Daly and Davis 2003;
Daly et al. 1998). Requirements for admission into this
program include having failed at other less restrictive
placement settings, having at least one Axis I diagnosis,
and having an IQ above 80. Comorbidity rates are fairly
high in this population, with 68% of the youth having
two or more classes of diagnosis (e.g., a behavioral disorder and a mood disorder). Of these youth, 340 (53.5%)
were wards of the state and 271 (42.6%) had their stay
funded by Medicaid. The overall sample means or percentages for the predictor variables used in the analysis
are shown in Table 1.
Procedure
All data used in the study came from the organization’s
administrative database. Admission data were collected
by admission counselors prior to entry to the program,
medication data were collected by nursing staff at the
time of admission, and initial problem behavior was collected by direct-care staff during the ﬁrst two weeks in
the program. The research protocols were reviewed and
approved by the organization’s internal review board
(IRB) according to federal guidelines.
Measures
Demographics
Demographic variables extracted from the administrative
database include: (a) gender, (b) age at admission, (c)
number of prior placements, (d) age at ﬁrst placement,
(e) race (recoded to Caucasian/minority), and (f) whether
youth had been sexually and/or physically abused (based
upon history provided by the referral source).
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Table 1. Sample means (SD) or percentages for the 14 predictor measures
M or %
Age at ﬁrst placement
Age at admission
Prior placement number
Male
Caucasian
Initial problem behavior
Aggression
(29.9)
Oppositional
(30.4)
Hyperactivity
Covert
Internalizing
Victim
Admission diagnosis
Behavior disorder
Mood disorder
Other disorders

10.2 (4.7)
14.3 (2.5)
3.6 (4.4)
54.2%
63.1%
14.7
37.9
16.5 (16.9)
4.8 (6.5)
9.1 (8.6)
28.3%
84.0%
57.7%
49.4%

Clinical Diagnosis
A comprehensive psychological assessment prior to admission was available for most youth. This assessment
was conducted by licensed clinicians in the community
who are not afﬁliated with the residential treatment facility. The order in which the diagnoses are listed in the
administrative data base does not indicate primary vs.
secondary diagnosis. The diagnoses listed for the youth
were collapsed into three non-exclusive categories (i.e.,
youth could have one or more diagnoses): (1) behavior
disorders, (2) mood disorders, and (3) other diagnoses
(e.g., reactive attachment disorder).
Behavioral Incidents
Daily observations of signiﬁcant youth behaviors come
from direct observation of behaviors gathered in a clinical management tool called the Treatment Progress Checklist (TPC). The TPC is a modiﬁed version of Chamberlain’s
Parent Daily Report (Chamberlain et al. 2006; Chamberlain and Reid 1987). The TPC report logs all signiﬁcant
events (e.g., property damage, self-destructive behavior,
physical assault) that occur at the setting during each
of the three shifts each day. Each recorded incident includes a descriptive narrative of the behavior or event,
and staff categorize each incident using at least one of 46
behavior codes. Each code has been operationalized so answers are consistent across staff entries. Some incidents
may include more than one code. Direct-care staff record
these events in a TPC (paper form) at the end of each
shift for each child (one form per day, divided into three
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sections, one section for each shift). All staff working
that shift (between 9 and 14 individuals) collaboratively
complete the TPC form for each youth. For this study,
behavioral incidents were grouped into 5 general areas:
oppositional, hyperactive, aggressive, internalizing, and
covert. Oppositional behavior is an aggregate of arguing,
complaining, deﬁance, irritable mood, not participating
in program, and swearing and/or obscenities. Hyperactive behavior is an aggregate of ﬁdgeting, homework incomplete, interrupting often, off-task behavior, and talking excessively. Aggressive behavior is an aggregate of
physical aggression, physical assault, physical assault
attempt, property damage, and threatening. Internalizing behavior is an aggregate of crying, negative self-statements, pouting, somatic complaints, and withdrawal. Covert behavior is an aggregate of inappropriate boundaries,
lying/cheating, secretive/suspicious behavior, stealing,
and teasing/provoking.
Staff are extensively trained to use the TPC and the
reliability of the daily observation of initial problem behavior in this population has been established previously.
Research using this behavioral coding process has found
an 83.5% interjudge agreement in regards to the “reportability” of youth behavior between direct-care staff
responding to 43 scenarios (Wright 2001). Additionally,
research examining the reliability of the coding process within the population for this program found kappa
coefﬁcients between 0.66 and 0.97 for codes assigned for
the same incident narratives (Larzelere 1996). Taken together, both at the level of reporting and coding, the behavioral coding process possesses adequate reliability.
The expression of problem behavior in youth often
changes during the ﬁrst few days in the PRTF. It frequently starts low and then escalates as youth become
more familiar with and test the boundaries of their new
environment. Moreover, the behavioral intervention itself is designed to reduce youth’s problem behaviors, and
signiﬁcant reductions in the behaviors measured by the
TPC occur over the ﬁrst couple of months (Huefner and
Vollmer 2014). We used the ﬁrst two weeks of behavioral
data in order to obtain stable data indicative behavioral
problems at the time of admission that was relatively less
impacted by suppression of the behavioral intervention.

information gleaned from the psychosocial history and
other information collected in the admissions process,
and contains a list of 50 problems (e.g., out of control of
parental instruction, physically assaultive toward peers,
school behavior problems, etc.). Three of the items (victim of neglect, victim of physical abuse, victim of sexual abuse) were used to create a dummy variable—having one or more of these items checked was scored as a
“yes” for victimization. The program does not use a formal measure of victimization, so there is no way to determine victimization status for youth for whom a PPC
was not completed.

Victimization

Data Analyses

Victimization status was obtained from a form called the
Presenting Problems Checklist (PPC), which is collected
separately from all the other data used in this research.
The PPC is used primarily by a separate division the organization, and is not systematically used by the PRTF
for either clinical or administrative purposes (hence its
use is sporadic). It is unlikely that completion of this
form is based on any attribute of the youth entering the
PRTF. The PPC is completed by admission staff based on

LCA was used to identify subgroups of youth with unique
proﬁle of psychotropic medication use (Lanza et al.
2003). The LCA was conducted with Mplus version 7.3
(Muthén and Muthén 2012). In this study, the six medication categories were modeled as dichotomous indicators of a categorical latent variable representing subgroup membership. A series of LCAs were conducted
with increasing numbers of classes, with ﬁt statistics
and the substantive meaning of the solutions being used

Psychotropic Medications
All medications that the youth brought with them at the
time of admission were recorded in the organization’s
database by a psychiatric nurse as part of the admission
process. Youth are sent to this residential program primarily because they have behavioral issues (whether or
not they have a formal behavioral disorder diagnosis).
Many of their psychotropic medications at the time of
admission are presumably aimed at helping them with
their behavioral issues. From the information available
to us, however, we cannot determine why youth were put
on these medications, what other mediations have been
tried, or even the extent to which the medications have
impacted their behavior prior to entering the program.
Complicating the matter, the psychotropic prescriptions
for each youth were often made independently by a variety of prescribers (psychiatrists, pediatricians, general
practitioners). Taken together, youth’s complex treatment
histories and multiple prescribers often result in medication patterns that are confusing to our psychiatrists and
clinicians, as well as others (see Kingsbury et al. 2001;
Rosenheck 2005).
For analysis, psychotropic medications were categorized into one of six categories: (1) antianxiety, (2) antidepressant, (3) antipsychotic, (4) mood stabilizer, (5)
stimulant/NRI (norepinephrine reuptake inhibitor), or
(6) alpha agonist. These categories are well established
and widely used in psychotropic medication research
(e.g., Jann et al. 2016; Olfson et al. 2009).
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to determine the number of classes. Fit indices included
the Bayesian Information Criteria (BIC), the Vuong-LoMendell-Rubin Likelihood Ratio Test (VLMR-LRT), and
the Bootstrapped Likelihood Ratio Test (BLRT). These indices, along with the substantive meaning, were used to
determine the best ﬁtting solution (Berlin et al. 2014).
The result with the smallest BIC is considered to be the
best ﬁtting. The VLMR-LRT and the BLRT compare a solution with a speciﬁc number of classes to an answer
with one less class. The null hypothesis for the VLMRLRT and BLRT is that a model with k classes and one with
k−1 classes are not different from each other. A decision
to reject the null hypothesis means that a solution with
k classes provides a better ﬁt to the data.
The 3-step approach advanced by Asparouhov and
Muthén (2014a,b) was used to examine the relation between subgroup membership and several variables. The
3-step approach was carried out in Mplus using the Auxiliary command (Muthén and Muthén 2012). The BCH
(Block, Croon, & Hagenaars, 2004) option is used with
the Auxiliary command to estimate mean-level differences between subgroup membership and continuous outcome variables (i.e., age at admission to the current program, prior number of out-of-home placements, and ﬁve
classes of problem behavior [aggressive, oppositional,
hyperactive, covert, and internalizing] expressed during
the ﬁrst two weeks of the current episode of care). Similarly, the DCAT (distal categorical outcome) command is
used with the Auxiliary command to examine the relation between subgroup membership and categorical outcomes (i.e., biological sex, race, and history of victimization [yes/no], and three classes of admission diagnosis
[behavior disorder, mood disorder, and other disorder]).
The BCH and DCAT are the preferred options for examining class membership differences across continuous and
categorical outcomes, respectively, and have been shown
to perform well (Asparouhov and Muthén (2014a,b).
Each of the auxiliary analyses for the 14 predictors
is an independent statistical analysis, creating the need
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to control for alpha. We chose to use Holm’s step-down
Bonferroni method to control for family-wise error rates
(Holm 1979), with the family-wise error rate set at .05.
Complete data were available for 362 (56.9%) youth;
12 of the 14 variables used in the present study had missing data. Three variables did not have any missing data
(psychotropic medications, age at admission, and gender), 11 variables had less than 2% of the sample missing
(age at ﬁrst placement, prior placement number, race, all
5 behavioral indicators, and the three diagnostic categories). Only one variable, victimization status, had substantial proportion of missing data at 43.1% missing. Missing
data for this variable was due to administrative failure
in inputting the data. The LCAs were based on complete
data (psychotropic medications), while the auxiliary analyses implemented list-wise deletion (the N for each analysis is shown in Table 3).

Results
Table 2 shows the ﬁt statistics for three LCA models (2,
3, and 4 class models) that were estimated. Examination
of the ﬁt statistics indicated that the 3-class model was
the best ﬁt for the data. The BIC, VLMR-LRT, and BLRT all
indicated that the 3-class solution provided the best ﬁt to
the data. We also examined the substantive meaning of
the 2, 3, and 4 class models. The 3-class solution seemed
to provide the most conceptually meaningful solution.
Entropy for the 3-class solution was acceptable (.70). The
pattern for the three class solution across the medication categories is shown in Fig. 1. The three medication
classes are (1) low/no psychotropic medications, (2) antidepressant and antipsychotic medications, and (3) multiple psychotropic medications. Table 3 shows that there
were signiﬁcant differences between the 3 latent classes
for 12 of the 14 predictor variables and lists the raw-score
averages. These differences are discussed below.

Table 2. Fit statistics for one, two, three, and four class models
Number
of classes

Log
likelihood

Number of free
parameters

BIC

VLMR-LRT

BLRT

Entropy

1

−2037

6

4112.8

n/a

n/a

n/a

2

−1887

13

3857.9

293.6*

300.1*

0.87

3

−1852.7

20

3834.5

67.09*

68.6*

0.70

4

−1849.8

27

3873.8

5.71

5.8

0.76

The null hypothesis for the Vuong-Lo-Mendell-Rubin Likelihood Ratio Test (VLMR-LRT) and the Bootstrapped Likelihood Ratio Test (BLRT)
is that models with k classes and one with k−1 classes are not different from each other. A decision to reject the null hypothesis means
that a solution with k classes provides a better ﬁt to the data. Underline indicates best ﬁtting solution for a particular ﬁt statistic.
* p < .001

322

H u e f n e r e t a l . i n J o u r n a l o f C h i l d a n d Fa m i ly S t u d i e s 2 6 ( 2 0 1 7 )

Fig. 1. Psychotropic medication
patterns for the three class
solution (class labels and
percentage of sample shown)
across the medication categories

Table 3. Univariate Chi-square scores testing for signiﬁcant differences for the LCA classes across the 14 predictor
measures
			
Low/no 		
			
psychotropic		
			
medications		
			
(n = 176)		
Overall χ2

N

Mean

S.E.

Anti-		
depressants/		
anti-psychotics
(n = 179)		

Multiple
psychotropic
medications
(n = 281)

Mean

Mean

S.E.

8.58a
12.95b
3.40
71.8%a
65.4%ab

0.32
0.21
0.32
4.8
3.6

27.06c
46.85c
23.75c
6.15a
12.43c
47.6%ab

3.00
2.37
1.47
0.58
0.70
4.4

S.E.

Age at ﬁrst placement
35.20*
633
10.84a
0.39
12.05b
0.45
Age at admission
73.34*
636
15.05a
0.17
15.59a
0.22
Prior placement number
6.15
634
4.53
0.48
3.11
0.29
Male
27.24*
636
61.2%a
4.3
31.0%b
5.2
Caucasian
7.26*
624
55.1%a
4.0
71.0%b
5.5
Initial problem behavior†						
Aggression
35.81*
636
7.26a
1.32
2.39b
2.10
a
Oppositional
28.17*
636
36.55
2.57
25.23b
2.63
Hyperactivity
47.75*
636
14.34a
1.07
7.28b
1.45
Covert
15.08*
636
4.70a
0.49
2.72b
0.50
Internalizing
66.84*
636
5.22a
0.50
7.45b
0.80
a
Victim‡
12.16*
362
34.8%
5.7
64.5%b
5.8
Admission diagnosis
				
.028
63.6%b
.069
Behavior disorder
21.09*
635
88.4%a
a
Mood disorder
66.02*
635
34.6%
.040
84.1%b
.046
Other disorders
0.40
635
48.1%
.041
47.9%
.048

96.5%c
54.2%c
51.3%

.019
.039
.035

† Problem behavior during the ﬁrst 2 weeks of episode of care.
‡ Victim status only available for a random subset of youth; see Method section for speciﬁc details.
* Signiﬁcant p < .05 correcting for family-wise error using Holm’s Bonferroni (Holm 1979).
The lettered superscripts following the class means indicate which means are statistically different; means that share a superscript letter
are not signiﬁcantly different.

Medication Latent Classes
Low/No Psychotropic Medication Class
More than a quarter of the youth are represented by the
low/ no psychotropic medications latent class (n = 176,

28%). Most youth in this class were not on any psychotropic medication at the time of admission, with limited numbers on an antidepressant, antipsychotic, or a
stimulant/NRI.
The low/no psychotropic medications youth had the
highest number of prior placements (M = 4.5), but this
was not signiﬁcantly higher than the antidepressant
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and antipsychotic medications youth. The initial levels
of problem behavior for the low/no psychotropic medications class was signiﬁcantly lower than the multiple
psychotropic medications youth and signiﬁcantly higher
than the antidepressant and antipsychotic medications
youth for all three of these behavioral categories. Additionally, the low/no psychotropic medications youth were
signiﬁcantly higher than the antidepressant and antipsychotic medications class for covert behaviors, and were
signiﬁcantly lower than the other classes for internalizing behavior (M = 5.2) problems. Low/no psychotropic
medications youth also had the lowest levels of victimization, but this was only signiﬁcantly lower than the antidepressant and antipsychotic medications youth. Conversely, the low/no psychotropic medications class had
the highest percentage of minority youth (45%), but
again this was only signiﬁcantly different from the antidepressant and antipsychotic medications class. The
level of aggression for the low/no psychotropic medications youth was signiﬁcantly higher than the antidepressant and antipsychotic medications youth, but only about
25% of the level of aggression of the multiple psychotropic medications youth. While the levels for all types of
problem behavior for this group were signiﬁcantly lower
than the multiple psychotropic medications class, they
were equally likely to have a behavioral disorder diagnosis (94%) at the time of admission as the multiple psychotropic medications youth. Conversely, low/no psychotropic medications youth were the least likely to have
a mood disorder diagnosis (24%) at admission. Low/
no psychotropic medications youth had a signiﬁcantly
higher percentage of males than the antidepressant and
antipsychotic medications class.
Antidepressant/Antipsychotic Class
More than a quarter of the youth fell into the antidepressant and antipsychotic medications latent class (n = 179;
28%). Almost every youth in this class was on an antidepressant at the time of admission (98%), with 81% also
being on an antipsychotic. Lower numbers of these youth
were on a stimulant (28%), mood stabilizer (22%), and/
or antianxiety (13%) medication. Youth in this class were
on an average of 2.9 psychotropic medications (SD = 1.1).
The antidepressant and antipsychotic medications
youth had the oldest age at ﬁrst out-of-home placement,
which was signiﬁcantly older than the low/no psychotropic medications and multiple psychotropic medications youth. They also had the oldest average age of admission to the current program, which was signiﬁcantly
older than the multiple psychotropic medications class.
The antidepressant and antipsychotic medications youth
had the lowest number of prior placements, but this was
not signiﬁcantly lower than the other groups. These youth

323

had the highest rate of victimization (65%), which was
signiﬁcantly higher than only the low/no psychotropic
medications youth. Antidepressant and antipsychotic
medications youth were signiﬁcantly more likely than the
other groups to be female (69%), and signiﬁcantly more
likely than the low/no psychotropic medications class to
be Caucasian (71%). The antidepressant and antipsychotic
medications youth had signiﬁcantly lower levels of aggression, oppositional, hyperactive, and covert problem
behaviors during the ﬁrst 2 weeks of program stay than
either the low/no psychotropic medications or multiple
psychotropic medications youth. This group’s level of internalizing problem behavior was signiﬁcantly higher
than the low/no psychotropic medications youth and
signiﬁcantly lower than the multiple psychotropic medications youth. Antidepressant and antipsychotic medications youth were signiﬁcantly less likely to have a behavioral disorder diagnosis and signiﬁcantly more likely
to have a mood disorder diagnosis than the other groups.
Multiple Psychotropic Medications Class
Just under half of the youth ﬁt the multiple psychotropic
medications class (n = 281; 44%). This group is characterized by the highest percentages of youth on antipsychotic (86%), mood stabilizer (60%), stimulant (50%),
and alpha agonist (32%) medications. There were also
multiple psychotropic medications youth on antidepressant (40%) and antianxiety (2%) medications. Youth in
this class were on an average of 3.2 psychotropic medications (SD = 1.6).
The multiple psychotropic medications youth had the
youngest average age at ﬁrst out-of-home placement,
but were only signiﬁcantly younger than the antidepressant and antipsychotic medications youth. Multiple psychotropic medications youth were also younger at the
time of admission to the current program, signiﬁcantly
younger than the other two groups. The multiple psychotropic medications class had the highest percentage of
males (72%), but this was only signiﬁcantly higher than
the antidepressant and antipsychotic medications class.
This group had signiﬁcantly higher averages for aggression, oppositional, hyperactive, and internalizing problem behaviors than either of the other groups. They were
signiﬁcantly higher than the antidepressant and antipsychotic medications class for covert behaviors. The multiple psychotropic medications youth had the highest percentage of behavioral disorder diagnoses (98%), but this
was only signiﬁcantly higher than the antidepressant and
antipsychotic medications class. Multiple psychotropic
medications youths’ level of mood disorder diagnosis was
signiﬁcantly lower than that for the antidepressant and
antipsychotic medications youth, but signiﬁcantly higher
than that for the low/no psychotropic medications youth.
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Discussion
We found that there are meaningful patterns in the prescribed psychotropic medications of youth who were admitted to an intensive psychiatric residential care program. Three distinct medication patterns emerged: the
low/ no medication latent class (most youth in this group
were on no psychotropic medication at all with a few on
antidepressants, antipsychotics, or stimulant/NRIs), the
antidepressants/antipsychotic medication latent class
(youth typiﬁed by almost all being on an antidepressant, with signiﬁcant numbers also being on an antipsychotic, stimulant/NRI, mood stabilizer, and/or antianxiety), and the multiple psychotropic medication latent
class (had the highest average number medication class
prescriptions, with most youth on an antipsychotic, with
the highest numbers on a mood stabilizer, stimulant/NRI,
or alpha agonist). Additionally, the use of auxiliary variables allowed a better understanding of the attributes
and characteristics of the individuals in each of the latent groups.
The low/no psychotropic medications class accounted
for about 28% of the youth. These were youth who
tended to be older than the program average. This group
also had the highest level of racial minority status (45%),
which might indicate that these youth had less access to
psychotropic medications. Previous research has found
that even controlling for clinical acuity, African-American and Latino children were less likely to report pastyear psychotropic medication use compared to Caucasian children (Leslie et al. 2003). There is a long history
of research indicating that racial minorities appear to
have unequal access to healthcare resources (Fossett et
al. 1992; Raghavan et al. 2014), but this ﬁnding does
not account for appropriateness of the medication (i.e.,
whether minorities might be under-medicated and/or
Caucasians might be over-medicated). Previous research
on the population examined in this study has found that
there are overall reductions in the medication rates for
youth (Huefner et al. 2014) and that there are not racial
differences in outcomes (Ringle et al. 2012).
Conversely, low/no psychotropic medications youth
had signiﬁcantly lower levels of victimization (35%) than
the antidepressant and antipsychotic medications class.
However, this is just the percentage of youth with a record of physical or sexual abuse at some point, and does
not indicate anything about the severity of that abuse.
Perhaps a better approach would be to account for the
extent (or count) of maltreatment (Felitti et al. 1998; Ippen et al. 2011). Research has found that higher levels of
trauma are associated with higher levels of psychotropic medication (Anda et al. 2007; Brack et al. 2012). This
may be another indication that youth in this class are not
under-medicated. The antidepressant and antipsychotic
medications class also accounted for about 28% of the

youth. These youth were older in age at ﬁrst-out-of-home
placement, more likely to be female, and had the highest
rate of victimization. These youth were also signiﬁcantly
more likely to have a mood disorder diagnosis, and almost all (98%) were admitted on an antidepressant. This
group was least likely to have a behavioral disorder diagnosis (58%), which may be associated with the lower
than average levels of aggressive, oppositional, hyperactive, and covert behavior during the ﬁrst two weeks of
program stay. Interestingly, this group was not the highest for internalizing behavior problems during the ﬁrst
two weeks of stay in the program. Histories of victimization and mood disorder are consistent with the use
of antidepressants and antipsychotics (Brack et al. 2012;
Burcu et al. 2014).
It is also notable that 81% in this group were also on
an antipsychotic. The association of a mood disorder diagnosis with high levels of antipsychotics and antidepressants is suggestive of anxious depression or severe mood
dysregulation (Carlson et al. 2009; Leibenluft 2011). This
pattern has also been associated with a bipolar diagnosis (Carlson et al. 2009; Findling et al. 2011), and selfharm/suicidality (Brunner et al. 2014; Smith 2005). The
antidepressant/antipsychotic combination aligns with an
emerging effectiveness literature, and is suggestive of adjunct pharmacotherapy for treatment-resistive depression (e.g., anxious depression; Chena et al. 2011; Marcus
et al. 2008; Papakostas 2010).
The multiple psychotropic medications class accounted
for about 44% of the youth. Youth in this group had the
highest average number of psychotropic medications
(3.2) at the time of admission. Multiple psychotropic medications youth had the youngest average age at ﬁrst outof-home placement and the youngest average age at the
time of admission to a psychiatric residential program.
It is interesting that individuals in the multiple psychotropic medications latent class tended to be placed into
out-of-home services at younger ages, which may indicate being more troubled and/or simply having had a longer period of time to accumulate more than one prescription for psychiatric medication.
Almost all of these youth had a behavior disorder diagnosis, and half of them had a mood disorder diagnosis at the time of admission. This group differs from the
antidepressant and antipsychotic group in terms of behaviorally acting out. The degree of disturbance in these
youth is reﬂected in their high levels of behavioral acting out during the ﬁrst two weeks of their program stay.
Multiple psychotropic medications youth expressed these
higher rates of initial problem behavior in spite of entering the program on the highest average number of psychotropic medications. Previous research has indicated
that much initial problem behavior for youth in the program studied here is aggressive in nature (Huefner et
al. 2014). Aggressive behavior itself has been associated
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with polypharmacy (Safer et al. 2003) and with dysregulated mood (Leibenluft 2011).
The pattern found in the multiple psychotropic medications latent class was similar to research which suggests that polypharmacy rates are highest for youth receiving antipsychotics (Dean et al. 2006). The high
percentages of youth in this class concurrently on mood
stabilizers, antipsychotics, and alpha agonists potentially
is troubling as these all carry the potential for serious
health-related side effects (Fontanella et al. 2009). The
high rates of polypharmacy for this class may indicate a
pattern where a high number of agents have been combined in an attempt to ﬁnd a medication or combination of medications that effectively improves a youth’s
symptoms and behavior (Steiner and Karnik 2009). Some
researchers have postulated that high pediatric polypharmacy rates result from insufﬁcient trials of monopharmacy (e.g., inadequate dose, sufﬁcient time frame,
etc.), symptom-based prescribing, clinical encounter time
constraints, managed care restrictions, and insufﬁcient
attention to psychosocial issues (Kingsbury et al. 2001;
Rosenheck 2005).
Our results found that the multiple psychotropic medications latent class, while having the highest rates of
behavioral diagnoses, was not signiﬁcantly higher than
the behavioral diagnosis rate for the low/no psychotropic medications class. However, it is very interesting to
note that the multiple psychotropic medication class had
signiﬁcantly higher rates of initial problem behavior than
either of the other medication classes (the exception being not signiﬁcantly higher than the low/no psychotropic medications class rate for covert behavior). The last
factor, initial problem behavior, might be seen as providing clinical justiﬁcation for the high medication rates, but
conversely, one could argue that problem behavior rates
should be suppressed by the elevated levels of concomitant/adjunctive medications (Grifﬁth et al. 2010), although problem behavior rates prior to medication administration were unknown in this sample.
Our results do show that the latent groups found in the
prescribed psychotropic medications at admission were
related to interesting patterns of clinical need. Arguably,
if severe mood dysregulation is accurate for the youth
in the antidepressant and antipsychotic medications latent class, then the pattern of psychotropic medications
makes sense and is supported by research as an appropriate treatment for these youth. Conversely, the medication
patterns seen in the multiple psychotropic medications
class do not conform to any supported clinical practice
and is suspect by its apparent excess. On the other hand,
given admission to an intensive residential program
which serves youth with high levels of behavioral and
emotional disturbance, there is the possibility that the
low/no psychotropic medication latent class may be under-medicated. In fact, that all these youth have been
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admitted to an intensive residential treatment program
suggests that their medication regimens need thoughtful reassessment using the principle of sufﬁciency as the
foundation for medication management (i.e., using just
enough medication as clinically indicated; Bellonci and
Huefner 2014).
This study examined medication patterns at the time
of admission to an intensive residential treatment center, which is a helpful initial step in understanding the
differing needs and challenges of youth with emotional
and behavioral problems. Future research needs to look
at how patterns of psychotropic medication use change
over time for this population of youth. For example, what
psychotropic medications are these youth on at the time
of discharge, and do changes in medication correspond
to changes in their diagnostic formulation? Additionally,
are there differences in how youth in the different latent
classes respond to the program intervention? Are youth
in the low/no psychotropic medications class more likely
to have a psychotropic medication added, and the multiple psychotropic medications class to have psychotropic
medications dropped? The adequacy of pharmacotherapy to meet the clinical needs of these youth was not addressed in this study, and also needs to be addressed in
future research. There is a need for longitudinal research
that focuses on the relationship between placement history and psychotropic medication trials. Finally, there is
a strong need for future research to examine the issue of
medication dosage data in children and adolescents. What
is the relationship between dosage and issues like treatment effectiveness, practitioner conformity to practice
guidelines, polypharmacy, and side effects?
One limitation of this study is the lack of standardized measures of psychopathology. Such measures were
only available for a limited number of the youth in the
study. With the caveat that we only looked at broad diagnostic categories and level of troubled behavior during the ﬁrst two weeks in the program, the results reported here emphasize the need to reassess children’s
clinical and pharmacological therapeutic needs. A second limitation is that the Auxiliary command in Mplus
does not allow for the examination of multiple outcome
variables simultaneously. As such, we are not able to investigate the three diagnostic dimensions together, and
this limits the conclusions that we can make about the
speciﬁcity of the relation between class membership and
diagnosis. However, our analyses take a signiﬁcant ﬁrst
step toward characterizing psychotropic medication use
patterns among high-risk youth using LCA and provide
a foundation on which future studies can build. Another
limitation is that we only looked at youth admitted to
one facility located in the Midwest. As it has been noted
that there can be regional patterns of psychotropic medication prescription (Aman et al. 2005; Radigan et al.
2005; Rawal et al. 2004), it is possible that our results
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reﬂect such a regional pattern. It should be noted, however, that the overall levels of psychotropic medication
use found in these programs are consistent with those
found in similar programs in other parts of the country
(Breland-Noble et al. 2004; Connor et al. 1998; Ryan et
al. 2008). Last of all, the PRTF does not use a systematic measure of victimization and the victimization data
used in this research comes from a form that is inconsistently completed by admissions staff. Both these issues
create a very real limitation for the use of the victimization data available to us, but we deemed victimization
status sufﬁciently important to include it in the analysis.
Our results are an initial effort towards grouping and
describing different classes of psychotropic medication
usage among youth entering an intensive residential
care program. Our ﬁndings highlight that many youth
in residential care are on multiple psychotropic medications, and that there is a critical need to evaluate this
practice. Our results also help explicate the patient and
clinical characteristics that underlie the latent psychotropic medication classes. These ﬁndings highlight the
need for more careful monitoring of the types and range
of medications that youth are prescribed. It is our belief that this information, and that of further research
examining the patterns of pediatric psychotropic medication use, will ultimately lead to improved, youth-centered prescribing practices.
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